Intervet Inc. announces the launch of the Titanium® line of cattle vaccines under the Intervet label as a component of a co-marketing agreement with Agri Laboratories Ltd.
Intervet Inc. announces the launch of the Titanium® line of cattlevaccines under the Intervet label as a component of a co-marketing agreementwith Agri Laboratories Ltd. The Titanium vaccine line is a modified-livedefensive for protection against bovine respiratory disease and will beco-marketed under labels from both Intervet and AgriLabs. Developed fromthe Signature Cell Line technology, Intervet-labeled Titanium vaccines offerthe latest in bovine technology, the company says. Titanium contains thenew modified-live Type 2 (Bolin 296) BVD strain, as well as the Type 1 (OregonC-24V) BVD strain. It also delivers the broadest protection available tocombat a BVD challenge, the company says. Titanium also has been provenin a 110-day challenge study to provide an extended duration of immunityfor protection against an IBR challenge. From an IBR and BVD safety perspective,Titanium is proven to be non-shedding, the company says. Titanium, withthe exception of the Pasteurella combination, also meets Beef Quality assuranceprogram requirements with subcutaneous administration and a low-volume 2-mldosage, the company says.
For fastest response call (800) 835-0541 or visit the Web site at